Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more
Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
The Center for Prevention of Progression is the first-of-its-kind clinic for patients with precursor conditions of hematologic malignancies. Building on Dana-Farber's past and ongoing research efforts of precursor conditions, the clinic evaluates individuals
diagnosed with these conditions or at high risk for disease development, and works with patients to manage their risk of disease progression.
Our goal is to increase early detection and improve treatment options for precursor conditions, so we can prevent these conditions from developing into blood cancers which are often incurable, or from resulting in other complications, such as cardiovascular
death or organ dysfunction.
As with many solid tumors, some blood cancers are preceded by precursor conditions. These conditions are sometimes found through routine blood tests, but often remain undiagnosed. Precursor blood conditions include:
Certain individuals are at higher risk for these conditions and should consider screening and counseling at the Center. These include:
Patients will be cared for a multidisciplinary team that harnesses Dana-Farber's leadership and expertise in hematologic malignancies, genetic risk, and prevention. This includes hematologists/oncologists who specialize in a patient's specific precursor
condition, as well as specialists in genetic risk and prevention, genetic counseling, psychosocial support, and other specialties as needed.
Irene Ghobrial, MD, specializes in care and research for multiple myeloma. She leads multiple research efforts focused on the precursor conditions of multiple myeloma — monoclonal gammopathy of undetermined significance and smoldering multiple myeloma
— including the PROMISE and PCROWD studies.
We welcome the opportunity to collaborate with you to evaluate and manage the care of patients with precursor hematologic conditions. To refer a patient, please call 617-582-9422.
Center for Prevention of Progression Appointments